Determination of the Minimal Residual Disease Threshold in Acute Myeloid Leukemia Treated with ‘ОМЛ-17’ and ‘mОМЛ-17’ Regimens

Irina Vladimirovna Galtseva, E.N. Parovichnikova, K.A. Nikiforova, Yu.O. Davydova, N.M. Kapranov, I.A. Lukianova, A.A. Ievleva, Yu.A. Chabaeva, Z.T. Fidarova, L. A. Kuzmina, V.V. Troitskaya, T.V. Gaponova, S.M. Kulikov,

DOI:

https://doi.org/10.21320/2500-2139-2025-18-4-340-346

BACKGROUND. Minimal residual disease (MRD) refers to the tumor cells detected in complete remission patients by highly sensitive methods (PCR and flow cytometry). Each treatment regimen requires the determination of MRD threshold, i.e., the leukemic cell count used for prognostic stratification of patients.

AIM. To determine the MRD threshold in acute myeloid leukemia (AML) treated with ‘ОМЛ-17’ and ‘mОМЛ-17’ regimens.

MATERIALS & METHODS. The study enrolled 73 AML patients (age ≤ 60 years). MRD was assessed by multicolor flow cytometry after induction cycles 1 and 2. Statistical analysis included Kaplan-Meier curve for assessing disease-free survival and ROC-survival curve for assessing MRD threshold.

RESULTS. Complete remission was achieved in 89.1 % of patients. MRD-negative status was reported after induction cycle 1 in 66.7 % of patients and after cycle 2 in 74.6 % of patients. By the ROC-survival curve, the MRD threshold values were determined as 0.1 % after induction cycle 1 and 0.03 % after cycle 2. With the threshold 0.1 %, the 3-year overall survival after induction cycle 1 was 47.1 % in patients with the MRD-positive status vs. 96.9 % in patients with the MRD-negative status, whereas after induction cycle 2 they were 85.8 % and 51.8 %, respectively.

CONCLUSION. Based on MRD monitoring after induction cycles 1 and 2 with ‘ОМЛ-17’ and ‘mОМЛ-17’ regimens, a group of patients at high risk for relapse can be identified. Critical MRD thresholds are 0.1 % after induction cycle 1 and 0.03 % after cycle 2.

  1. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008;26(30):4944–51. doi: 10.1200/JCO.2007.15.9814. DOI: https://doi.org/10.1200/JCO.2007.15.9814
  2. San Miguel JF, Vidriales MB, López-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98(6):1746–51. doi: 10.1182/blood.v98.6.1746. DOI: https://doi.org/10.1182/blood.V98.6.1746
  3. Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889–97. doi: 10.1200/JCO.2012.45.9628. DOI: https://doi.org/10.1200/JCO.2012.45.9628
  4. Buccisano F, Maurillo L, Piciocchi A, et al. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplant. 2017;52(3):473–5. doi: 10.1038/bmt.2016.308. DOI: https://doi.org/10.1038/bmt.2016.308
  5. Паровичникова Е.Н., Лукьянова И.А., Троицкая В.В. и др. Разработка программной терапии больных острыми миелоидными лейкозами в возрасте моложе 60 лет, основанной на принципах дифференцированного воздействия. Терапевтический архив. 2021;93(7):753–62. doi: 10.26442/00403660.2021.07.200946. [Parovichnikova E.N., Lukianova I.A., Troitskaya V.V., et al. Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects. Terapevticheskii arkhiv. 2021;93(7):753–62. doi: 10.26442/00403660.2021.07.200946. (In Russ)] DOI: https://doi.org/10.26442/00403660.2021.07.200946
  6. Wood B. Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol. 2004;75:559–76. doi: 10.1016/s0091-679x(04)75023-2. DOI: https://doi.org/10.1016/S0091-679X(04)75023-2
  7. Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol. 2013;999:123–36. doi: 10.1007/978-1-62703-357-2_8. DOI: https://doi.org/10.1007/978-1-62703-357-2_8
  8. Van der Velden VHJ, van der Sluijs-Geling A, Gibson BES, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia. 2010;24(9):1599–606. doi: 10.1038/leu.2010.153. DOI: https://doi.org/10.1038/leu.2010.153
  9. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–91. doi: 10.1182/blood-2017-09-801498. DOI: https://doi.org/10.1182/blood-2017-09-801498

Keywords:

acute myeloid leukemias, minimal residual disease, flow cytometry

License

Copyright (c) 2025 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

Author Biography

  • Irina Vladimirovna Galtseva, National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

    MD, PhD

Downloads

Published

01.10.2025

Issue

Vol. 18 No. 4 (2025)
MYELOID TUMORS

How to Cite

Galtseva I.V., Parovichnikova E.N., Nikiforova K.A., et al. Determination of the Minimal Residual Disease Threshold in Acute Myeloid Leukemia Treated with ‘ОМЛ-17’ and ‘mОМЛ-17’ Regimens. Clinical Oncohematology. Basic Research and Clinical Practice. 2025;18(4):340–346. doi:10.21320/2500-2139-2025-18-4-340-346.

Most read articles by the same author(s)

1 2 3 4 > >>